FDA OK's 2 HIV drugs: BMS' Evotaz, J&J's Prezcobix
This article was originally published in Scrip
Executive Summary
The FDA was on a roll on 29 January approving new combination treatments for HIV-1 infection, with Bristol-Myers Squibb’s Evotaz (atazanavir/cobicistat) and Johnson & Johnson subsidiary Janssen's Prezcobix (darunavir/cobicistat) both winning the agency’s nod